Medicine and Dentistry
Adjuvant Therapy
6%
Adverse Event
23%
Alcohol Consumption
18%
Arm
15%
Body Mass Index
31%
Brain Tumor
31%
Brainstem
31%
Breast Cancer
31%
Cancer Growth
6%
Cancer Therapy
40%
Charlson Comorbidity Index
6%
Chemoradiotherapy
9%
Clinician
5%
Combined Therapy
9%
Drug Therapy
8%
Gadolinium
15%
Ganglioglioma
31%
General Practitioner
31%
Glioblastoma
100%
Glycated Hemoglobin
13%
Hippocampus
15%
Hypofractionated Radiotherapy
31%
Intracranial Tumor
5%
Logistic Regression Analysis
14%
Magnetic Resonance Imaging
15%
Malignant Neoplasm
20%
Maturity Onset Diabetes of the Young
31%
Neoplasm
55%
Neuro-Oncology
34%
Obesity
6%
Oncology
5%
Optic Nerve
15%
Overall Survival
32%
Phase I Trials
31%
Photon Therapy
10%
Physical Activity
31%
Pituitary Gland
15%
Postmenopause
12%
Premenopause
25%
Prognostic Factor
31%
Progression Free Survival
14%
Proton Therapy
31%
Quality of Life
5%
Radiation Therapy
54%
Randomized Controlled Trial
31%
Recurrent Disease
60%
Short Form 36
6%
Skull Defect
8%
Survival Rate
8%
Tumor Treating Fields
93%
Keyphrases
Alcohol Consumption
15%
Body Mass Index
31%
Cancer-associated
31%
Chiasm
31%
Comprehensive Cancer Center
10%
Confidence Interval
12%
Dice Values
10%
Difference in Mean
12%
Early Breast Cancer
31%
First-void Urine
15%
Fisher-Kolmogorov
10%
Gadolinium Contrast
10%
Gadolinium-enhanced MRI
10%
Glioma
12%
Glioma Grading
12%
Glioma Growth
10%
Glioma Patients
31%
Increased Surface Area
10%
Ligase Chain Reaction
31%
Mean Dose
12%
Medical Trainees
31%
Menopausal Status
15%
Microscopic Tumors
10%
Optic Tract
10%
Partnership Practice
13%
Patient Selection
12%
Patterns of Care Study
31%
Photon Therapy
12%
Physical Activity
31%
Physical Comorbidity
31%
Physical Function
10%
Physical Functioning
31%
Poor Prognosis
10%
Postmenopausal Women
31%
Primary Breast Cancer
10%
Prognostic Factors
31%
Proton Radiotherapy
31%
Proton Therapy
31%
Radiotherapy Target
31%
Recurrence Risk
20%
Recurrent Glioblastoma
31%
Risk Structure
20%
Skull Defect
8%
Specialty Choice
10%
Surface Mapping
10%
Transcription-mediated Amplification
31%
Treatment Modalities
12%
Tumor
10%
Tumor Growth Model
10%
Tumor Response Assessment
10%
